Selected announcements | CHINAHONGQIAO expects annual Net income to nearly double year-on-year; GOLDLION HOLD receives a premium for privatization, resuming trading today.

CHINAHONGQIAO expects that the Net income for the year ending December 31, 2024, may increase by around 95% year-on-year; China Coal Energy's Commodity coal sales for the first 11 months were 0.256 billion tons, showing a decrease of 1.9% year-on-year; November sales were 25.8 million tons, representing a year-on-year increase of 11.4%.

cls.cnDec 18 08:20

The first patient administration of the IB phase clinical trial of Yiming Anke (01541.HK) IMM0306 has been completed.

Eiming Angke - B (01541.HK) announced that the group's independently developed IMM0306 (a novel innovative drug consisting of a bispecific antibody targeting CD47xCD20) has successfully completed its first patient administration in the phase Ib clinical trial for treating neuromyelitis optica spectrum disorders, with no adverse events reported.

AASTOCKSDec 18 02:32

Hong Kong Stock Announcement | Alibaba-W: Plans to sell Silver, HeartSky Medical: ScienCrown's transcatheter implanted aortic valve system has obtained the medical instruments registration certificate.

GOLDLION HOLD (00533) received a premium of approximately 24.85% for privatization from Chairman Zeng Zhiming, resuming trading on December 18. IMMUNEONCO-B (01541): The Phase IB clinical trial for IMM0306 to treat optic neuritis spectrum disease has completed the first patient dosing.

Zhitong FinanceDec 17 22:36

ImmuneOnco Biopharmaceuticals Doses 1st Patient in NMOSD Drug Trial

MT NewswiresDec 17 19:48

IMMUNEONCO-B (01541.HK): The first patient has been dosed in the Phase IB clinical trial of IMM0306 for the treatment of Neuromyelitis Optica Spectrum Disorders.

On December 17, Gelonghui announced that IMMUNEONCO-B (01541.HK) has reported the successful completion of the first patient dosing in the phase Ib clinical trial of IMM0306 (an Innovative Drugs bispecific antibody targeting CD47xCD20) for the treatment of neuromyelitis optica spectrum disorder (NMOSD), with no adverse event reports. IMM0306, independently developed by the group, is a bispecific molecule targeting cluster of differentiation 47 (CD47) and cluster of differentiation 20 (CD20), and is the first CD47 and CD20 bispecific molecule to enter clinical stages globally. IMM030

Gelonghui FinanceDec 17 18:04

Quick view of the Hong Kong market | All three major indexes fell, with the tech index dropping over 1%; tech stocks and Insurance stocks weakened, Bilibili fell more than 5%; FOSUN TOURISM resumed trading and rose by 80%.

Network Technology stocks fell broadly, JD-SW fell by 2.80%, MEITUAN-W fell by 2.79%; Digital Health stocks declined, ZA ONLINE fell by 1.85%, MediChina fell by 1.41%; Real Estate Developers' stocks also fell, SUNAC rose by 5.36%, SHK PPT fell by 2.55%;

Futu NewsDec 11 16:21